Wall Street analysts forecast that OptiNose, Inc. (NASDAQ:OPTN – Get Rating) will announce sales of $17.97 million for the current quarter, Zacks reports. Two analysts have issued estimates for OptiNose’s earnings, with the highest sales estimate coming in at $18.00 million and the lowest estimate coming in at $17.93 million. OptiNose reported sales of $11.96 […]
OptiNose (NASDAQ:OPTN – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or […]
OptiNose, Inc. (NASDAQ:OPTN – Get Rating) COO Ramy A. Mahmoud sold 8,219 shares of the firm’s stock in a transaction that occurred on Wednesday, March 16th. The shares were sold at an average price of $2.11, for a total value of $17,342.09. The sale was disclosed in a document filed with the Securities & Exchange […]
Zacks Investment Research downgraded shares of OptiNose (NASDAQ:OPTN – Get Rating) from a buy rating to a sell rating in a research note published on Saturday morning, Zacks.com reports. According to Zacks, “OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and […]
Zacks Investment Research upgraded shares of OptiNose (NASDAQ:OPTN – Get Rating) from a hold rating to a buy rating in a report released on Tuesday, Zacks.com reports. The firm currently has $3.00 target price on the stock. According to Zacks, “OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of […]